Sentences with phrase «median overall survival»

In one study, patients treated with surgery, radiation therapy and chemotherapy had median overall survival times of 32 months.

In the most recent results of the trial, treatment increased median overall survival by two months in patients treated according to protocol.

There was no statistically significant difference in median overall survival.

The approval came on the heels of the first phase III clinical trial ever shown to improve overall survival in patients with the disease, with median overall survival of 10.1 months, versus 6.4 months in the control group.

Median overall survival for patients on selumetinib was 11.8 months, compared with 9.1 months for those on chemotherapy, but the difference was not statistically significant.

With a median follow - up of 36.7 months, the researchers found no survival benefit of chemoradiotherapy compared with chemotherapy, with median overall survival from the date of the first randomization of 15.2 months and 16.5 months, respectively.

Mean progression - free survival was 3.1 months with regorafenib and 1.5 months with placebo, while median overall survival was 10.6 months for regorafenib and 7.8 months with placebo.

Regardless of the type of therapy, the prognosis has been a dismal reported median overall survival of 12 - 16 months and high rate of relapse within 1 year [1 - 3].

Dendreon's study of 512 men demonstrated that when compared to a placebo, Provenge increased three - year survival by 38 percent and extended median overall survival by 4.1 months.

Median overall survival for patients with mucosal melanoma was 11.3 months.

After a median follow up of 19 months, median overall survival hadn't been reached.

The median overall survival rate of 16.5 months exceeds the historical average survival of six - 12 months with standard chemotherapy.

The median progression free survival was 8.9 months and median overall survival was 14.4 months.

In patients with HLA - A2 and unmethylated MGMT, those in the control group had a median overall survival of about 12 months, compared with about 16 months in the treatment group.

The median progression - free survival was 2.5 months and the median overall survival was 26.1 months.

«Patients who were treated with pembrolizumab lived significantly longer than patients who were treated with chemotherapy; the median overall survival was 10.3 months with pembrolizumab and 7.4 months with chemotherapy.

As of April 2015, with a median follow up of 30.1 months, the media progression free survival was 19.1 months and the median overall survival had increased to 32.1 months.

Median overall survival for woman in the chemotherapy plus bevacizumab treatment was 42.2 months, compared with 37.3 for those receiving chemotherapy alone.

Median overall survival was 10.4 months for SRS alone and 7.4 months for SRS plus WBRT.

Median overall survival was 6.7 months, and median recurrence - free survival was 8.1 months.

Median overall survival for total laryngectomy patients was 61 months versus 39 months for patients receiving chemoradiation.

Investigators found that by adding docetaxel at the beginning of the ADT regimen, median overall survival was improved by 13.6 months.

The median overall survival time for all patients was 62 weeks compared to the 29 - week average of more than 800 patients at a similar stage of the disease who had been treated with chemotherapy.

At five years, the rates for disease - free and overall survival were 26 percent and 40 percent, respectively, with a median overall survival of four years.

In the 520 patients who had high - extent disease (whose cancer had spread to major organs and / or the bones), treatment with ADT plus docetaxel had an even greater benefit: these men had a median overall survival of 49.2 months versus 32.2 in the ADT - only group — a difference of 17 months.

This translated into a median overall survival of 57.6 months for men who received early chemotherapy compared with 44 months in the group given ADT as the only initial treatment — more than a year of additional life.

Those with mutations had a median overall survival of 19.1 months, compared with 9.3 months in those with EGFR mutations.

For the total study group, median overall survival was 20 months: 13.4 months in AZA arm and 6.7 months in LDAC arm.

The median progression - free survival time for recurrent ovarian cancer is 3 months, and median overall survival is less than 12 months.

Median progression - free survival was 3.6 months (3.1 — 3.9 months) and median overall survival was 11.1 months (9.5 — 12 months).

The median overall survival was 9 months in the entire chemotherapy group and 7.7 months in the erlotinib group, for a hazard ratio of 1.14 (95 % CI, 0.88 — 1.49; P = 0.313).

The median overall survival for previously untreated patients was 18.6 months.

The median progression - free survival was 4.3 months, and median overall survival was 6.4 months.

With a median follow - up of 8.6 months, the median overall survival was 16.4 months for cohort A, 11.8 months for cohort B, and 5.2 months for cohort C.

The median overall survival for napabucasin was 4.4 months compared with 4.8 months for placebo.

Retrospective case reports suggest that adults may benefit from consolidation with allogeneic HSCT during their first CR following chemotherapy with one study observing a median overall survival of 38.5 months [5].

Median overall survival was higher in the inotuzumab ozogamicin arm (7.7 months vs 6.2 months) but these results did not reach statistical significance.

Overall response rate among the 47 previously treated was 68 %, and the median overall survival was 11.25 months.

The median overall survival was 12.5 months, and the 12 - month overall survival rate was 58 %.

The median overall survival was 40 months for all stages of disease.

The median overall survival was 32.9 months for left - side primary compared with 19.6 months for right - side primary (P <.0001).

Median overall survival was not reached.

In RATIFY (Randomized AML Trial In FLT3 in patients less than 60 Years old, NCT00651261), for which Stone was first author, median overall survival was 74.7 months with chemotherapy plus midostaurin and 25.6 months with chemotherapy plus placebo (P = 0.009).

Renal impairment is associated with poor prognosis and short survival duration, with a median overall survival of less than 2 years.

The treatment resulted in a median overall survival (OS) of longer than 3 years in both arms of the trial (median OS, 38.2 months for irradiation vs 36.6 months for nonmyeloablating chemotherapy alone; hazard ratio, 1.11 [95 % CI, 0.65 — 1.91]-RRB-.

The median overall survival of patients in the Phase 1 resection injection study, where Toca 511 was injected into the wall of the resection cavity after removal of the tumor, exceeds historical controls across a variety of previously reported clinical trials.

For newly diagnosed GBM patients treated with current standard of care, median progression free survival is just 6.9 months, and median overall survival is 14.6 months.